Earnings & Reporting

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

A powerful new genomic tool is turning genetic doubt into diagnostic certainty, helping thousands of patients understand their true hereditary cancer risk.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

Superior Health's acquisition of Pulse Home Health, backed by private equity, signals a major shift in Louisiana's booming home health and hospice market.

The firm's assets grew on market gains, but significant client outflows and shrinking fees triggered a sharp stock drop, revealing key industry pressures.

A landmark survey reveals a massive capital rotation as 96% of institutions chase AI and 81% move to private markets to navigate a fragmenting world.

As Crown Crafts preps its Q3 earnings, investors watch to see if strategic shifts can overcome financial pressures in the competitive juvenile products market.

Markets are calm, but concerns over US Federal Reserve independence add a new layer of risk to global trade, threatening borrowing costs and stability.

With its Q4 and full-year 2025 earnings call on the horizon, Cactus Inc.'s consistent dividend payout offers a glimpse into its financial stability.

As OneMain CEO Doug Shulman prepares for a key conference, all eyes are on the lender's strategy for navigating a complex economic and regulatory landscape.

As Par Pacific sets to release its Q4 2025 results, investors are watching for updates on its new renewables venture and sustained financial performance.

A new analysis of malpractice claims reveals the top drivers of patient harm in cardiology, offering critical insights to save lives and protect careers.

Humana is rolling out 'Agent Assist,' an AI tool for 20,000 advocates, aiming to enhance empathy and efficiency, not replace its human workforce.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

Celebrating 100 years in the Caribbean, Holland America Line doubles down on its classic, relaxed cruise style, contrasting with today's mega-ship trend.

A new survey shows Canadians are cutting back on dating due to costs, with Gen Z leading the charge for financial transparency and frugal romance.

The convenience store giant released preliminary 2025 financials as its subsidiary, ARKO Petroleum Corp., launches a high-stakes IPO roadshow.